Gilead: HIV Franchise Woes Highlight Cancer Follies
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
Zacks Investment Research on MSN7h
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. On ...
moneycontrol.com22h
Gilead Sciences
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...